RPG Life Sciences Board Approves FY26 Results, Recommends ₹24 Dividend, Appoints New Director
RPG Life Sciences announced its audited financial results for the quarter and year ended March 31, 2026. The board recommended a dividend of ₹24 per share for FY26, subject to shareholder approval. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
The declaration of financial results and dividend recommendation are significant for shareholders. The appointment of a new director also adds to the company's governance structure, contributing to a medium impact.
The company reported positive financial results and recommended a dividend, alongside the appointment of a new independent director, which are generally viewed favorably by the market.
RPG Life Sciences Limited's Board of Directors met on April 29, 2026, from 3:00 PM to 6:30 PM IST. The board approved the audited financial results, both standalone and consolidated, for the quarter and year ended March 31, 2026. The audit reports received were with an unmodified opinion.
Furthermore, the Board recommended a dividend of ₹24 per equity share (300%) for FY 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of such approval.
In a significant development, Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for a term of five years, from April 29, 2026, to April 28, 2031. Dr. Samdani, a physician with over two decades of experience in Internal Medicine and Critical Care, is not related to any existing director or key managerial personnel of the company. The company also approved an amendment to its Code of fair disclosure, internal procedures, and conduct for regulating, monitoring, and reporting of trading by designated persons.
The trading window for dealing in the company's securities will open 48 hours after the declaration of the financial results.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.